297 related articles for article (PubMed ID: 15970124)
1. [Advances in adjunctive pharmacological therapy for percutaneous coronary interventions].
Benito B; Masotti M; Betriu A
Rev Esp Cardiol; 2005 Jun; 58(6):729-43. PubMed ID: 15970124
[TBL] [Abstract][Full Text] [Related]
2. [Stents in interventional cardiology].
Grinius V; Navickas R; Unikas R
Medicina (Kaunas); 2007; 43(3):183-9. PubMed ID: 17413246
[TBL] [Abstract][Full Text] [Related]
3. [The new antithrombotic agents].
Meyer Samama M
Presse Med; 2005 Oct; 34(18):1309-14. PubMed ID: 16269995
[TBL] [Abstract][Full Text] [Related]
4. Optimal antithrombotic treatment for percutaneous coronary intervention.
Kadakia RA; Ferguson JJ
Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
[TBL] [Abstract][Full Text] [Related]
5. A guide to drug use during percutaneous coronary intervention.
Choo JK; Young JJ; Kereiakes DJ
Drugs; 2002; 62(18):2589-601. PubMed ID: 12465999
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet intervention in acute coronary syndrome.
Arora RR; Rai F
Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
[TBL] [Abstract][Full Text] [Related]
7. What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Brodie BR
Catheter Cardiovasc Interv; 2008 May; 71(6):816-21. PubMed ID: 18412079
[TBL] [Abstract][Full Text] [Related]
8. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
Moliterno DJ;
Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
[TBL] [Abstract][Full Text] [Related]
9. Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial.
Kereiakes DJ
Rev Cardiovasc Med; 2009; 10(2):72-82. PubMed ID: 19593319
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparins in the cardiac catheterization laboratory.
Montalescot G; Cohen M
J Thromb Thrombolysis; 1999 Jun; 7(3):319-23. PubMed ID: 10373715
[No Abstract] [Full Text] [Related]
11. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
Bosanquet N; Jönsson B; Fox KA
Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436
[TBL] [Abstract][Full Text] [Related]
12. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
13. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale.
Mehran R; Brodie B; Cox DA; Grines CL; Rutherford B; Bhatt DL; Dangas G; Feit F; Ohman EM; Parise H; Fahy M; Lansky AJ; Stone GW
Am Heart J; 2008 Jul; 156(1):44-56. PubMed ID: 18585496
[TBL] [Abstract][Full Text] [Related]
14. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
Dangas GD; Caixeta A; Mehran R; Parise H; Lansky AJ; Cristea E; Brodie BR; Witzenbichler B; Guagliumi G; Peruga JZ; Dudek D; Möeckel M; Stone GW;
Circulation; 2011 Apr; 123(16):1745-56. PubMed ID: 21482968
[TBL] [Abstract][Full Text] [Related]
15. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
16. [Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
Niessner A; Niessner H; Huber K
Herz; 2001 Apr; 26 Suppl 1():36-41. PubMed ID: 11349625
[TBL] [Abstract][Full Text] [Related]
17. The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.
Wang TY; Magid DJ; Ting HH; Li S; Alexander KP; Roe MT; Peterson ED
Am Heart J; 2014 Jun; 167(6):833-9. PubMed ID: 24890532
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory.
Deutsch E
Am Heart J; 1999 Dec; 138(6 Pt 2):S577-85. PubMed ID: 10577465
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
